Develops small molecule drugs for hepatitis and respiratory diseases.
Jun 2026Revenue $65.3M/yrExpenses $124M/yr
Fell below break-even Apr 2020Cash runway ≈ 5.1 years from Jun 2026
Figures by year
When will Enanta Pharmaceuticals be profitable again?
Its expenses passed its revenue in Apr 2020. In the 12 months to Jun 2026, revenue was $65.3M and expenses $124M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Sep 2025 | $65.3M | $151M | −$85.3M |
| Sep 2024 | $67.6M | $189M | −$122M |
| Sep 2023 | $79.2M | $216M | −$137M |
| Sep 2022 | $86.2M | $210M | −$124M |
| Sep 2021 | $97.1M | $207M | −$110M |
| Sep 2020 | $122M | $164M | −$41.6M |
| Sep 2019 | $205M | $168M | $36.7M |
| Sep 2018 | $207M | $118M | $88.3M |
| Sep 2017 | $103M | $78.2M | $24.6M |
| Sep 2016 | $88.3M | $57.4M | $30.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.